Central lung cancer
Conditions
Interventions
Observation group:N/A
Sponsors
The First Affiliated Hospital of Ningbo University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years; 2.Patients with chest CT highly suspicious for lung cancer, scheduled for diagnostic bronchoscopic biopsy. 3.Provide written informed consent and voluntarily participate in this clinical study.
Exclusion criteria
Exclusion criteria: 1.Severe cardiopulmonary disease, coagulation disorders, intolerance to anesthesia, psychiatric disorders or severe neurosis, or any other contraindications to flexible bronchoscopy (including patients on anticoagulation and/or antiplatelet therapy who have not discontinued such medications =5 days prior to the procedure); 2.Intra-procedural oxygen desaturation (SpO2 decline) or inability to tolerate bronchoscopy; 3.Unable to comply with study procedures for any reason, or judged unsuitable by the investigator; 4.Significant active endobronchial bleeding on bronchoscopy with anticipated risk of clinical worsening; 5.Incomplete or missing key clinical information required for study assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The CIELAB color difference between bleeding areas and abnormal mucosal lesion areas under RDI and WLI modes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visibility grading (4 levels) for abnormal mucosal lesions;Diagnostic sensitivity of RDI-guided biopsy in AFI-positive patients;Amount of post-biopsy bleeding and bleeding severity grade; | — |
Countries
China
Contacts
Public ContactZhongbo Chen
The First Affiliated Hospital of Ningbo University
Outcome results
None listed